Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from multiple daily insulin to twice-daily insulin degludec/aspart in type 2 diabetes mellitus
ChiCTR2000037600Phase 4Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by Peking Union Medical College Hospital. Primary endpoint: HbA1c. Started Aug 2020; status: recruiting.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2000037600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037600.